Recombinant Enzymes for accessing drug metabolites
To access phase I drug metabolites, Hypha provide several key enzymes including a set of proprietary diverse microbial CYPs called PolyCYPs, as well as human recombinant aldehyde oxidase (AOX1) and all five human isoforms of flavin monooxygenase (FMOs). Each enzyme is cloned into E.coli and validated against a panel of relevant drug substrates to demonstrate utility.
A set of 18 PolyCYPs enzymes, AOX1 and FMO3 are available in a kit form called PolyCYPs+.
PolyCYPs+ kits contain all co-factors needed to screen a drug substrate for metabolites, as well as a control compound and formulant for poorly water soluble test compounds. More information on PolyCYPs+ kits can be found here.
In addition to the enzymes supplied in PolyCYPs+ kits, Hypha also offer a service to screen compounds against any of our recombinant enzymes, including all five human FMO isoforms.
All recombinant enzymes are fully scalable to provide larger quantities of metabolites. Scale-up vials of PolyCYPs+ enzymes are available, as well as the ability to scale-up large quantities of metabolites at Hypha as a service offering. We can also undertake purification and structure elucidation of metabolites.
Contact us at enquiries@hyphadiscovery.co.uk for more information.